Jeong Hyoung-Oh, Lee Hayoon, Kim Hyemin, Jang Jinho, Kim Seunghoon, Hwang Taejoo, Choi David Whee-Young, Kim Hong Sook, Lee Naeun, Lee Yoo Mi, Park Sehhoon, Jung Hyun Ae, Sun Jong-Mu, Ahn Jin Seok, Ahn Myung-Ju, Park Keunchil, Lee Semin, Lee Se-Hoon
Department of Biomedical Engineering, Ulsan National Institute of Science and Technology (UNIST), Ulsan, Republic of Korea.
Korean Genomics Center, UNIST, Ulsan, Republic of Korea.
iScience. 2022 Oct 13;25(11):105358. doi: 10.1016/j.isci.2022.105358. eCollection 2022 Nov 18.
Malignant pleural effusion (MPE) is a complication of lung cancer that can be used as an alternative method for tissue sampling because it is generally simple and minimally invasive. Our study evaluated the diagnostic potential of non-small-cell lung carcinoma (NSCLC)-associated MPE in terms of understanding tumor heterogeneity and identifying response factors for EGFR tyrosine kinase inhibitor (TKI) therapy. We performed a single-cell RNA sequencing analysis of 31,743 cells isolated from the MPEs of 9 patients with NSCLC (5 resistant and 4 sensitive to EGFR TKI) with EGFR mutations. Interestingly, lung epithelial precursor-like cells with upregulated and expression were enriched in the EGFR TKI-resistant group. Moreover, upregulated transitional effector T cells, and plasmacytoid dendritic cells were significantly enriched in the EGFR TKI-resistant patients. Our results suggest that cellular plasticity and immunosuppressive microenvironment in MPEs are potentially associated with the TKI response of patients with EGFR-mutated NSCLC.
恶性胸腔积液(MPE)是肺癌的一种并发症,由于其通常操作简单且微创,可作为组织采样的替代方法。我们的研究从了解肿瘤异质性和识别表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)治疗的反应因素方面评估了非小细胞肺癌(NSCLC)相关MPE的诊断潜力。我们对从9例EGFR突变的NSCLC患者(5例对EGFR TKI耐药,4例敏感)的MPE中分离出的31743个细胞进行了单细胞RNA测序分析。有趣的是, 和 表达上调的肺上皮前体样细胞在EGFR TKI耐药组中富集。此外, 上调的过渡效应T细胞和浆细胞样树突状细胞在EGFR TKI耐药患者中显著富集。我们的结果表明,MPE中的细胞可塑性和免疫抑制微环境可能与EGFR突变的NSCLC患者的TKI反应相关。